AZ’ Farxiga shows 47% reduction in kidney function decline
The SGLT2 inhibitor was evaluated in 17,160 patients with type II diabetes.
Read More
Tag: SGLT2
US green light for Pfizer/Merck diabetes therapies
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
Read More
Mundipharma bags rights to sell Janssen’s Invokana, Vokanamet
Janssen Pharmaceutica has entered into an exclusive agreement with Mundipharma under which the latter will distribute its diabetes drugs Invokana and Vokanamet in countries in the European Economic Area (EEA) and Switzerland.
Read More
UK sees first global launch of AZ’ diabetes combo Qtern
Adults in the UK with type II diabetes have gained a new treatment option to keep blood sugar levels under control with the launch of AstraZeneca’s Qtern in the country.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
